PRESS RELEASES
December 13, 2011 - Avaxia Biologics is Awarded Patent for its Proprietary Orally Active Antibody for Celiac Disease
Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company was awarded U.S. Patent 8,071,101, "Antibody Therapy for Treatment of Diseases Associated With Gluten Intolerance."
This patent, which expires on May 27, 2029, provides broad coverage for treating celiac disease using orally administered antibodies produced by the Company's proprietary platform technology. This newly issued patent includes claims covering the composition of matter for Avaxia's AVX-176 antibody, currently in development for celiac disease.
"We are pleased to receive this new patent," stated Barbara Fox, PhD, CEO of Avaxia Biologics. "This is an important milestone for our company as it is our first issued patent and it validates that the company can obtain composition of matter claims for products derived from our antibody technology platform. We are actively building a strong IP portfolio with additional patent applications that will cover the broad range of disease applications the company has created with its oral antibody technology." Dr. Fox added, "This first patent covers AVX-176, an orally administered antibody designed to bind to gluten, the dietary protein that provokes celiac disease in susceptible patients. We are currently conducting an NIH supported program to advance the development of AVX-176 into pre-clinical models of celiac disease. Preliminary in vitro data are encouraging and we hope to be able to develop a product in the near future."
ABOUT CELIAC DISEASE Celiac disease is an inherited, autoimmune disease in which the lining of the small intestine is damaged from eating gluten and other proteins found in wheat, barley, rye, and possibly oats. Celiac disease is also known as celiac sprue, nontropical sprue, and gluten-sensitive enteropathy. The disease can develop at any point in life, from infancy to late adulthood. The symptoms of celiac disease can vary significantly from person to person with the most common being abdominal bloating and pain, chronic diarrhea, vomiting, constipation and weight loss. There is no medication available to treat the disease. Patients must follow a lifelong gluten-free diet in an attempt to avoid symptoms. More than 2 million people in the United States have the disease, or about 1 in 133 people.
ABOUT AVAXIA BIOLOGICS, INC. Avaxia Biologics is a development-stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract. The antibodies are designed to treat both diseases of the GI tract and metabolic diseases. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes and obesity.
November 10, 2011 - Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company completed its first close of $2.2 million of a Series A angel-led financing. Cherrystone Angels of Providence, Rhode Island led the round, with participation from Boston Harbor Angels and other undisclosed individuals. Mr. Robert Manning, the co-Chairman of Cherrystone Angels, will join the Avaxia board. Mr. Manning has served as a senior executive at Citigroup and on a number of early-stage company boards, including SmartCells.
Dr. Barbara Fox, Avaxia's founder and CEO, commented, "This investment will allow us to aggressively pursue the development of our AVX-470 anti-TNF oral antibody and prepare Avaxia to initiate a clinical trial in inflammatory bowel disease next fall. When coupled with the funding we have received from BARDA (Biomedical Advanced Research and Development Authority) to develop AVX-470 for GI Acute Radiation Syndrome, our investors have a unique opportunity to participate in the rapid creation of value in two important disease areas. We are in advanced discussions with a limited number of other qualified investors as we work to complete this planned round of financing. The angel community's response to Avaxia has been very gratifying."
The funds from this financing will be used to manufacture drug to be used in the clinical trial and to conduct final pre-clinical studies in advance of a Phase 1b clinical trial in patients with inflammatory bowel disease, being planned for the second half of 2012. The company has raised $4.3 million in non-dilutive financing prior to this equity round. In addition to a loan from the Massachusetts Life Sciences Center and several SBIR grants, the company was awarded a $2.9 million, 2-year contract with BARDA that fully funds the initial research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident.
ABOUT CHERRYSTONE ANGEL GROUP The Cherrystone Angel Investor Group, based in Providence, Rhode Island, offers early stage investment funds to companies in Rhode Island, Connecticut and Massachusetts.
ABOUT AVAXIA BIOLOGICS, INC. Avaxia Biologics is a development-stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract. The antibodies are designed to treat both diseases of the GI tract and metabolic diseases. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes and obesity.
October 26, 2011 - Avaxia Biologics Opens New Office and Labs in Lexington, Massachusetts
Avaxia Biologics, a development stage company focusing on oral antibody therapeutics that act locally within the gastrointestinal tract, today hosted a ribbon cutting ceremony for the company's new office and lab space at 128 Spring Street in Lexington, Massachusetts. Advancing from the virtual stage, the office and labs will serve as the new hub for the company. Speakers at the event included Avaxia Biologics founder & CEO Barbara Fox, Massachusetts Life Sciences Center Vice President for Communications Angus McQuilken, and MassBio Director of Economic Development & Global Affairs Peter Abair. The company received $375,000 in early-stage loan financing through the Massachusetts Life Sciences Center's Accelerator Program in 2010 and has added 9 new employees this year. The Life Sciences Center is the agency charged with implementing the state's ten-year, $1 billion Life Sciences Initiative.
"Avaxia is dedicated to the development of new medications to treat serious diseases: Crohn's disease, ulcerative colitis, acute radiation syndrome, and other diseases of the GI tract," said Fox. "Over the coming year, we will continue to build our team and will start testing our lead product in patients with inflammatory bowel disease. Moving into our new lab facility is an important step in our growth, and we'd like to use this opportunity to thank the Massachusetts Life Sciences Center and all of our collaborators, partners, advisors and investors for their support."
"Avaxia Biologics is a great example of how a home-grown company can expand and create jobs with support from the Life Sciences Center," said Governor Deval Patrick. "I congratulate Avaxia on this milestone in the company's growth."
"Avaxia Biologics is a terrific company, and the Center is proud of the investment we have made in Avaxia's growth," said Massachusetts Life Sciences Center President & CEO Susan Windham-Bannister, Ph.D. "We are pleased to welcome the company to their new headquarters, and we look forward to a continued partnership with Avaxia as they grow and advance their important science here in Massachusetts."
"Avaxia is one of the fine examples of Massachusetts talent and innovation growing and thriving right here," said MassBio Director of Economic Development Peter Abair. "We know they will play a lead role in the continued strength of the life sciences supercluster."
"Avaxia's new office and lab in Lexington continues the tradition of groundbreaking, even revolutionary advances for humanity in this town," said State Representative Jay Kaufman (D-Lexington). "It's great to have such an important addition to the community. For the citizens and patients of Lexington and the commonwealth, thank you Avaxia for all you have done and will do for us."
August 3, 2011 - Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today it was awarded a contract with the Biomedical Advanced Research and Development Authority (BARDA), for the research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident. The contract totals $2.9 million over 2 years provided that key milestones are achieved. Should Avaxia's program meet its anticipated endpoints at the end of this contract, the company hopes to pursue future opportunities with BARDA.
Dr. Barbara Fox, Avaxia's CEO, commented, "We are very pleased to receive this contract and are proud to be working on this program related to our country's national defense. With this funding, we will be advancing our oral antibody product through the key efficacy studies needed to support the product's use as a nuclear threat countermeasure. This contract will permit us to complete the pre-clinical pharmacology studies for this potential therapy. We look forward to working with BARDA to develop a novel drug that can effectively protect the gastrointestinal tract from radiation damage.
This award provides Avaxia with a new drug development program that is of significant benefit to the company. Besides providing the company with additional scientific infrastructure, the research to be conducted on this therapeutic will contribute to and support our innovative technology platform and bolster work being done in the related field of inflammatory bowel disease. Also, should the project meet its targets, the manufacturing and sales of a radiation mitigation drug will increase the commercial opportunities for the company."
ABOUT BARDA The Biomedical Advanced Research and Development Authority (BARDA), is part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services. BARDA provides a comprehensive integrated portfolio approach to the advanced research and development, stockpile acquisition, innovation, and manufacturing infrastructure building of the necessary vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products for public health medical emergencies including chemical, biological, radiological, and nuclear threats, and pandemic influenza, and emerging infectious diseases. For additional information, visit www.hhs.gov/aspr.
March 10, 2011 - Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease. This Phase I award provides Avaxia with approximately $145,000 in research and development funds. If early results are promising, the Company could receive an additional $1 million in Phase II funding.
"We are delighted to have been awarded this grant from the NIH in recognition of the potential of our novel approach to the treatment of celiac disease," said Barbara S. Fox, Ph.D., Avaxia's founder and CEO. "This NIH support provides the funding we need to advance the development of our anti-gluten antibody into pre-clinical models of celiac disease, which is a serious lifelong inherited autoimmune condition, affecting more than 2 million children and adults in the U.S. alone.
ABOUT CELIAC DISEASE Celiac disease is an inherited, autoimmune disease in which the lining of the small intestine is damaged from eating gluten and other proteins found in wheat, barley, rye, and possibly oats. Celiac disease is also known as celiac sprue, nontropical sprue, and gluten-sensitive enteropathy. The disease can develop at any point in life, from infancy to late adulthood. The symptoms of celiac disease can vary significantly from person to person with the most common being abdominal bloating and pain, chronic diarrhea, vomiting, constipation and weight loss. There is no medication available to treat the disease. Patients must follow a lifelong gluten-free diet in an attempt to avoid symptoms. More than 2 million people in the United States have the disease, or about 1 in 133 people.
November 4, 2010 - Avaxia Biologics Awarded Qualifying Therapeutic Discovery Grant
Avaxia Biologics, Inc., a biotechnology company developing oral antibodies for diseases of the GI tract, announced today that that it has been awarded a $244,497 grant under the IRS' Qualifying Therapeutic Discovery Project (QTDP) program. The grant was awarded in recognition of Avaxia's development program of AVX-470 for the treatment of gastrointestinal inflammatory disorders. The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer. The QTDP program was created by Congress on May 21, 2010 under Section 48D of the Internal Revenue Code, as enacted under the Patient Protection and Affordable Care Act.
Dr. Barbara Fox, CEO of Avaxia, commented, "We are very appreciative of the recognition and support provided by this cash award for our AVX-470 program that has the potential to treat inflammatory gastrointestinal diseases. Also, this award provides needed capital to support continued breakthrough medical innovation at Avaxia and job creation in our community."
ABOUT GASTROINTESTINAL INFLAMMATORY DISEASES Gastrointestinal inflammatory diseases are associated with significant personal and societal costs. For example, the primary symptoms of both Crohn's disease and ulcerative colitis are abdominal pain, diarrhea and bleeding. These diseases typically presents at a young age, and most patients require lifelong therapy. Chronic drug therapy, hospitalization, and surgery are common and are associated with significant morbidity. Approximately 1 million people in the U.S. suffer from these diseases, with the prevalence equally divided between Crohn's disease and ulcerative colitis. A study carried out in the early 1990s estimated the direct and indirect economic burden of $1.8 - $2.6 billion per year.
ABOUT AVAXIA BIOLOGICS, INC. Avaxia Biologics (www.avaxiabiologics.com) is an early stage company developing orally-delivered antibody therapeutics. The antibodies are designed to treat both diseases of the GI tract and systemic diseases where the disease targets are accessible in the GI tract. Avaxia has a proprietary antibody platform and is developing products for oral mucositis, inflammatory bowel disease, and diabetes and obesity.
June 28, 2010 - Avaxia Biologics Receives Massachusetts Life Sciences Center Funding to Develop Oral Antibody Therapeutics for Oral Mucositis, Inflammatory Bowel Disease, Diabetes and Obesity
Avaxia Biologics, Inc., a biotechnology company developing oral antibodies for diseases of the GI tract, announced today that it is one of four early-stage life science companies to receive an Accelerator Program loan from the Massachusetts Life Sciences Center (MLSC). MLSC, a quasi-public agency tasked with implementing the state's ten-year, $1 billion Life Sciences Initiative, announced that Avaxia Biologics was authorized to receive $375,000 to continue product development and file new patents for its orally delivered antibody therapeutics aimed at disease targets accessible through the mouth and gastrointestinal (GI) tract.
"We are delighted to have been awarded this loan from the MLSC," said Barbara S. Fox, Ph.D., Avaxia's founder and CEO. "The support of the MLSC provides the funding we need to accelerate the development of our therapeutic programs and to advance the building of a strong intellectual property portfolio to support these drug products."
Dr. Fox continued, "We are pleased that the MLSC has recognized the potential therapeutic opportunities our approach brings to areas of unmet medical needs and Avaxia welcomes this validation of our programs. The GI tract is a uniquely privileged space that has been previously inaccessible to monoclonal antibody therapy. Avaxia's lead products are antibodies that are stable in the GI tract and are targeted at oral mucositis, inflammatory bowel disease, diabetes and obesity. We believe our approach will expand upon the proven utility of antibody therapeutics and open a new chapter in human therapeutics."
ABOUT AVAXIA BIOLOGICS, INC. Avaxia Biologics (www.avaxiabiologics.com) is a private, early stage company developing orally-delivered antibody therapeutics using a proprietary antibody platform. The company is pursuing products for oral mucositis, inflammatory bowel disease, and diabetes and obesity.
Avaxia's lead product is a proprietary anti-TNF antibody to be administered to the oral cavity of patients suffering from mucositis. The antibody is designed to reduce the pain and ulceration associated with this serious side effect of cancer treatment. Avaxia is also developing a proprietary anti-TNF antibody to be administered orally to patients suffering from inflammatory bowel disease. Avaxia is also conducting discovery programs in the field of diabetes and obesity, targeting critical intestinal receptors associated with glucose metabolism.
The company has its corporate offices in Burlington, MA and its research laboratories in Watertown, MA.
ABOUT THE MASSACHUSETTS LIFE SCIENCES CENTER The Massachusetts Life Sciences Center ("the Center") is a quasi-public agency of the Commonwealth of Massachusetts tasked with implementing the Massachusetts Life Sciences Act, a ten-year, $1 billion initiative that was signed into law in June of 2008. The Center's mission is to create jobs in the life sciences and support vital scientific research that will improve the human condition. This work includes making financial investments in public and private institutions that are advancing life sciences research, development and commercialization as well as building ties between sectors of the Massachusetts life sciences community. For more information, visit www.masslifesciences.com.
April 1, 2010 - Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Inflammatory Bowel Disease
Avaxia Biologics, Inc., a biotechnology company developing oral antibodies for diseases of the GI tract, announced today that it has been awarded a Phase I Small Business Innovation Research grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, to support the development of a novel antibody therapeutic for inflammatory bowel disease (IBD). This Phase I award provides Avaxia with approximately $213,000 in research and development funds. If early results are promising, the Company could receive an additional $750,000 in Phase II funding.
Avaxia is developing a proprietary anti-TNF antibody to be administered orally to patients suffering from IBD. IBD is a chronic inflammatory disorder of the gastrointestinal tract. There are two types of inflammatory bowel disease: Crohn´s disease, primarily affecting the small intestine; and, ulcerative colitis, affecting only the colon. Approximately 1 million people in the U.S. suffer from IBD. Currently marketed parenteral anti-TNF antibodies are highly effective in treating both Crohn’s disease and ulcerative colitis; however, because they are delivered by injection they neutralize TNF throughout the body and their use is associated with serious side effects, including the reactivation of tuberculosis and a long-term risk of malignancy. Avaxia’s approach will develop an anti-TNF antibody that has a lower risk of systemic immunosuppression and can be used as a first-line therapy for inflammatory bowel disease. The grant Avaxia just received will fund key pre-clinical studies of the antibody in a well-established animal model of IBD.
"We are delighted to have been awarded this grant from the NIH," said Barbara S. Fox, Ph.D., Avaxia’s founder and CEO. "Our preliminary in vivo animal data indicates that AVX-470, our orally active anti-TNF antibody, protects the intestinal lining from the damaging effects of radiation. This support from the NIH now provides the funding we need to advance the development of this antibody into pre-clinical models of IBD."
Avaxia is carrying out the grant-funded research in collaboration with Biomodels LLC, a Watertown-based pre-clinical drug research organization. Biomodels specializes in animal models of gastrointestinal diseases, such as IBD. "We are looking forward to working closely with Avaxia Biologics scientists in developing and testing a drug that could lead to an orally effective therapy for IBD," said Edward Fey, managing partner of Biomodels.
ABOUT IBD. IBD is associated with significant personal and societal costs. The primary symptoms of both Crohn’s disease and ulcerative colitis are abdominal pain, diarrhea and bleeding. IBD typically presents at a young age, and most patients require lifelong therapy. Chronic drug therapy, hospitalization, and surgery are common and are associated with significant morbidity. Approximately 1 million people in the U.S. suffer from IBD, with the prevalence equally divided between Crohn’s disease and ulcerative colitis. A study carried out in the early 1990s estimated the direct and indirect economic burden of IBD at $1.8 - $2.6 billion per year.
ABOUT AVAXIA BIOLOGICS, INC. Avaxia Biologics (www.avaxiabiologics.com) is an early stage company developing orally-delivered antibody therapeutics. The antibodies are designed to treat both diseases of the GI tract and systemic diseases where the disease targets are accessible in the GI tract. Avaxia has a proprietary antibody platform and is developing products for oral mucositis, inflammatory bowel disease, and diabetes and obesity.
ABOUT BIOMODELS LLC. Biomodels (www.biomodels.com), a preclinical drug research organization founded in 1997, develops and conducts predictive translational studies for biotechnology and pharmaceutical companies, particularly in the areas of cancer, cancer supportive care, radiation therapy, and inflammatory diseases. The company specializes in (non-GLP) efficacy studies that optimize dose, schedule and define mechanism of action. The company also has particular expertise in modeling inflammatory diseases, including those conditions affecting the gastrointestinal tract. Biomodels’ studies enable organizations to more readily identify lead compounds, decrease the time to a clinical trial and increase the chance of clinical success. Biomodels is headquartered in Watertown, MA.
February 4, 2010 - David Poorvin, Ph.D. named Chief Business Officer
Avaxia Biologics, Inc., a private biotech company developing oral antibody products for disease targets that can be reached through the mouth and the gastrointestinal tract, today announced the appointment of David Poorvin, Ph.D., as Chief Business Officer. In this position, Dr. Poorvin will be responsible for leading the Company's business development activities.
"David brings more than 35 years of business development and drug development research in the biotechnology and pharmaceutical industry,” said Avaxia Chief Executive Officer Barbara Fox, Ph.D. “His successful record of alliance creation and new product development makes him uniquely qualified to help Avaxia build into the future.”
From 2004 to present, Dr. Poorvin served as an Executive-in-Residence at Oxford Bioscience Partners, a biotechnology venture capital firm. Prior to joining Oxford Bioscience Partners, Dr. Poorvin worked at Schering-Plough for 22 years, the last 10 as head of Business Development. Dr. Poorvin had also held positions of Director of Clinical Research at Schering-Plough and at Pfizer Pharmaceuticals. He was responsible for several NDA programs and product approvals at both companies, including such drugs as Procardia and Imdur. Poorvin started his career in the pharmaceutical industry at Lederle Laboratories, were he directed pre-clinical research in the cardiovascular area.
Dr. Poorvin received his B.A. degree from Hunter College of the City University of New York. He received his Ph.D. from Rutgers University where he subsequently was awarded a post-doctoral fellowship in cardiovascular research. Dr. Poorvin is a member of several professional organizations, including the Licensing Executive Society. Dr. Poorvin currently sits on the board of directors of several biotech companies.
ABOUT AVAXIA BIOLOGICS, INC. Avaxia Biologics (www.avaxiabiologics.com) is developing oral antibody products for diseases and disease targets that can be reached through the mouth and the gastrointestinal tract. Avaxia’s products are bovine polyclonal antibodies, isolated from the early milk of immunized cows. Nature has designed these antibodies to be both stable to gastric digestion and safe for oral consumption. The company has built a proprietary technology platform on this natural source of antibodies, with unique advantages in product safety, cost and convenience. Just as importantly, the platform offers more rapid clinical development at a greatly reduced cost. Avaxia is using the platform technology to develop medications to treat serious diseases, many of them currently untreated by existing technologies.
September 16, 2009
Avaxia Biologics, Inc., a biotechnology company developing oral antibodies for disease targets accessible via the GI tract, announced today that it has been awarded a Phase I SBIR grant from the National Institute of Dental and Craniofacial Research to support the development of a novel antibody therapeutic for oral mucositis.
Avaxia is developing a polyclonal anti-TNF antibody to be administered to the oral cavity of patients suffering from mucositis. The antibody is designed to reduce the pain and ulceration associated with this serious side effect of cancer treatment. The grant will fund key pre-clinical studies of the antibody in a well-established animal model of radiation-induced oral mucositis.
"We are delighted to have been awarded this grant from the NIH," said Barbara S. Fox, Avaxia's founder and CEO. "Our preliminary data indicate that an anti-TNF antibody, delivered topically to a damaged mucosal membrane, will limit the severity of the inflammatory response induced by ionizing radiation. The support of the NIH provides both the funding we need to advance the development of this much needed therapeutic, and critical scientific validation of our approach."
Avaxia is carrying out the grant-funded research in collaboration with Biomodels LLC, a Watertown-based pre-clinical drug research organization. Biomodels specializes in animal models of toxicities associated with chemotherapy and radiation therapy used for the treatment of cancer and is a world leader in the study of cancer treatment-related mucosal injury (mucositis) .
"We are looking forward to working closely with Avaxia Biologics scientists in developing and testing a drug that could lead to an effective therapy for oral mucositis, a debilitating side effect that impacts virtually every patient who undergoes aggressive cancer treatment," said Edward Fey, managing partner of Biomodels.
Avaxia and Biomodels anticipate extending their productive collaboration to other therapeutic areas, including inflammatory bowel disease and GI enteritis and fibrosis.
ABOUT ORAL MUCOSITIS. Oral mucositis is a serious side effect of cancer chemotherapy and radiation therapy. According to a 2008 report from the National Comprehensive Cancer Network, mucositis has "emerged as the most significant adverse symptom of cancer therapy reported by patients." Mucositis is associated with severe pain and risk of infection, necessitating the use of systemic narcotics and the insertion of a feeding tube to provide nutrition. Most significantly, when mucositis develops, the dose and frequency of cancer treatment is often reduced, leading to a significant decrease in both short-term efficacy and long-term disease-free survival. There are no approved medications for the treatment of mucositis associated with most forms of cancer treatment.
ABOUT AVAXIA BIOLOGICS, INC. Avaxia Biologics (www.avaxiabiologics.com) is an early stage company developing orally-delivered antibody therapeutics. The antibodies are designed to treat both diseases of the GI tract and systemic diseases where the disease targets are accessible in the GI tract. Avaxia has a proprietary antibody platform and is developing products for oral mucositis, inflammatory bowel disease, and diabetes and obesity.
ABOUT BIOMODELS LLC. Biomodels (www.biomodels.com), a preclinical drug research organization founded in 1997, develops and conducts predictive translational studies for biotechnology and pharmaceutical companies, particularly in the areas of cancer, cancer supportive care, radiation therapy, and inflammatory diseases.
The company specializes in (non-GLP) efficacy studies that optimize dose, schedule and define mechanism of action. The company also has particular expertise in modeling inflammatory diseases, including those conditions affecting the gastrointestinal tract. Biomodels' studies enable organizations to more readily identify lead compounds, decrease the time to a clinical trial and increase the chance of clinical success. Biomodels is headquartered in Watertown, MA.
